nach oben

Erschienen in:

2021 | Psychopharmaka bei Kinderwunsch und Schwangerschaft | OriginalPaper | Buchkapitel

14. Psychopharmaka in Schwangerschaft und Stillzeit

verfasst von : PD Dr. med. Michael Paulzen, Otto Benkert

Erschienen in: Kompendium der Psychiatrischen Pharmakotherapie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Es wird eine praxisrelevante Übersicht zu den Risiken von Psychopharmaka in Schwangerschaft und Stillzeit gegeben. Sehr ausführlich wird das Risiko von Antidepressiva besprochen.

Anderson KN, Ailes EC, Lind JN et al (2020) Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997–2011. Schizophr Res 215:81–88CrossRef

Biffi A, Cantarutti A, Rea F et al (2020) Use of antidepressants during pregnancy and neonatal outcomes: an umbrella review of meta-analyses of observational studies. J Psychiatr Res 124:99–108CrossRef

Cuomo A, Goracci A, Fagiolini A (2018) Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. J Affect Disord 228:229–237CrossRef

Damkier P, Videbech P (2018) The safety of second-generation antipsychotics during pregnancy: a clinically focused review. CNS Drugs 32(4):351–366CrossRef

Dathe K, Schaefer C (2019) The use of medication in pregnancy. Dtsch Arztebl Int 116:783–790PubMedPubMedCentral

Datta P, Baker T, Hale TW (2019) Balancing the use of medications while maintaining breastfeeding. Clin Perinatol 46(2):367–382CrossRef

DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) für die Leitliniengruppe Unipolare Depression (2015) S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression – Langfassung, 2. Aufl. Version 2. http://www.depression.versorgungsleitlinien.de. Zugegriffen: 13. Mai 2018

Dragioti E, Solmi M, Favaro A et al (2019) Association of antidepressant use with adverse health outcomes: a systematic umbrella review. JAMA Psychiatry 76(12):1241–1255CrossRef

Ellfolk M, Leinonen MK, Gissler M et al (2020) (2020) Second-generation antipsychotics and pregnancy complications. Eur J Clin Pharmacol 76((1):107–115CrossRef

Fitton CA, Steiner MFC, Aucott L et al (2020) In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. Acta Psychiatr Scand 141(1):21–33CrossRef

Fornaro M, Maritan E, Ferranti R et al (2020) Lithium exposure during pregnancy and the postpartum period: a systematic review and meta-analysis of safety and efficacy outcomes. Am J Psychiatry 177(1):76–92CrossRef

Hernandez-Diaz S, Huybrechts KF, Desai RJ et al (2018) Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study. Neurology 90(4):e342–e351CrossRef

Huybrechts KF, Hernández-Díaz S, Patorno E et al (2016) Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry 73(9):938–946CrossRef

Huybrechts KF, Bröms G, Christensen LB et al (2018) Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the International Pregnancy Safety Study Consortium. JAMA Psychiatry 75(2):167–175CrossRef

Huybrechts KF, Bateman BT, Pawar A et al (2020) Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. BMJ 368:m237CrossRef

Kaltenbach K, O’Grady KE, Heil SH (2018) Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes. Drug Alcohol Depend 185:40–49CrossRef

Lugo-Candelas C, Cha J, Hong S (2018) Associations between brain structure and connectivity in infants and exposure to selective serotonin reuptake inhibitors during pregnancy. JAMA Pediatr 172(6):525–533CrossRef

Mesches GA, Wisner KL, Betcher HK (2020) A common clinical conundrum: antidepressant treatment of depression in pregnant women. Semin Perinatol 25:151229CrossRef

Molenaar NM, Bais B, Lambregtse-van den Berg MP (2020) The international prevalence of antidepressant use before, during, and after pregnancy: a systematic review and meta-analysis of timing, type of prescriptions and geographical variability. J Affect Disord 264:82–89CrossRef

Nechanská B, Mravčík V, Skurtveit S (2018) Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway. Addiction 113(7):1286–1294CrossRef

Onken M, Mick I, Schaefer C (2018) Paliperidone and pregnancy – an evaluation of the German Embryotox database. Arch Womens Ment Health 21(6):657–662CrossRef

Ornoy A, Koren G (2019) SSRIs and SNRIs (SRI) in pregnancy: effects on the course of pregnancy and the offspring: how far are we from having all the answers? Int J Mol Sci 20(10):2370CrossRef

Patorno E, Bateman BT, Huybrechts KF et al (2017a) Pregabalin use early in pregnancy and the risk of major congenital malformations. Neurology 88(21):2020–2025CrossRef

Patorno E, Huybrechts KF, Bateman BT et al (2017b) Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med 376(23):2245–2254CrossRef

Paulzen M, Goecke TW, Stingl J et al (2017a) Pregnancy exposure to citalopram – therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. Prog Neuropsychopharmacol Biol Psychiatry 79(Pt B):213–219CrossRef

Paulzen M, Goecke TW, Stickeler E et al (2017b) Sertraline in pregnancy – therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. J Affect Disord 212:1–6CrossRef

Paulzen M, Goecke TW, Kuzin M et al (2017c) Pregnancy exposure to quetiapine – therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood and obstetrical outcomes. Schizophr Res 195:252–257CrossRef

Paulzen M, Schneider H, Schoretsanitis G (2019a) Therapiesicherheit durch „Therapeutisches Drug Monitoring“ Pharmakotherapie bipolarer Störungen in Schwangerschaft und Stillzeit. NeuroTransmitter 7–8:40CrossRef

Paulzen M, Stingl JC, Augustin M et al (2019b) Comprehensive measurements of intrauterine and postnatal exposure to lamotrigine. Clin Pharmacokinet 58(4):535–543CrossRef

Paulzen M, Schoretsanitis G, Gründer G et al (2020) Pregnancy exposure to venlafaxine – therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes. J Affect Disord 266:578–584CrossRef

Pinheiro EA, Wisner KL, Clark CT (2018) Quetiapine dose adjustments in pregnant and postpartum women with bipolar disorder. J Clin Psychopharmacol 38(1):89–91CrossRef

Rose S, Dotters-Katz SK, Kuller JA (2020) Electroconvulsive therapy in pregnancy: safety, best practices, and barriers to care. Obstet Gynecol Surv 75(3):199–203CrossRef

Schoretsanitis G, Augustin M, Saßmannshausen H et al (2019) Antidepressants in breast milk; comparative analysis of excretion ratios. Arch Womens Ment Health 22(3):383–390CrossRef

Schoretsanitis G, Spigset O, Stingl JC et al (2020a) The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. Expert Opin Drug Metab Toxicol 16(5):431–440CrossRef

Schoretsanitis G, Westin AA, Deligiannidis KM et al (2020b) Excretion of antipsychotics into the amniotic fluid, umbilical cord blood, and breast milk: a systematic critical review and combined analysis. Ther Drug Monit 42(2):245–254CrossRef

Sheehy O, Zhao JP, Bérard A (2019) Association between incident eExposure to benzodiazepines in early pregnancy and risk of spontaneous abortion. JAMA Psychiatry 76(9):948–957CrossRef

Sinha P, Goyal P, Andrade C (2017) A meta-review of the safety of electroconvulsive therapy in pregnancy. J Ect 33(2):81–88CrossRef

Sujan AC, Rickert ME, Öberg AS et al (2017) Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring. JAMA 317(15):1553–1562CrossRef

Westin AA, Brekke M, Molden E et al (2017) Changes in drug disposition of lithium during pregnancy: a retrospective observational study of patient data from two routine therapeutic drug monitoring services in Norway. BMJ Open 7(3):e15738CrossRef

Titel: Psychopharmaka in Schwangerschaft und Stillzeit
verfasst von: PD Dr. med. Michael Paulzen
Otto Benkert
Verlag: Springer Berlin Heidelberg
Buch: Kompendium der Psychiatrischen Pharmakotherapie
Print ISBN: 978-3-662-61752-6

Electronic ISBN: 978-3-662-61753-3

Copyright-Jahr: 2021
DOI: https://doi.org/10.1007/978-3-662-61753-3_14

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

14. Psychopharmaka in Schwangerschaft und Stillzeit

Zusammenfassung

Neu im Fachgebiet Psychiatrie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Psychiatrie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko